Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)

4,6000 -0,0100 (-0,22%) Alla chiusura: 03:04PM CST

Guangdong Hybribio Biotech Co.,Ltd.

D5-3-3-4, North High-tech Zone
Chaozhou Economic Development Experimental Zone
Chaozhou 521000
China
86 76 8285 2923
https://www.hybribio.cn

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 2.669

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Jianyu Wang	GM & Director	N/D	N/D	1961
Mr. Qinghui Li	Finance Director	N/D	N/D	1965
Mr. Longxu Xie	Deputy GM & Director	N/D	N/D	1970
Mr. Zhisheng Guan	Executive Deputy GM & Non Independent Director	N/D	N/D	1984
Mr. Yi Chen	Deputy GM & Board Secretary	N/D	N/D	1979
Ms. Danrong Weng	Deputy General Manager	N/D	N/D	1981

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CNY.

Descrizione

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. The company was founded in 2003 and is based in Chaozhou, China.

Governance aziendale

L'ISS Governance QualityScore di Guangdong Hybribio Biotech Co.,Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.